Plasmin inhibitors in the prevention of systemic effects during thrombolytic therapy: Specific role of the plasminogen-binding form of α2-antiplasmin
- 30 May 1990
- journal article
- research article
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 15 (6) , 1212-1220
- https://doi.org/10.1016/s0735-1097(10)80003-8
Abstract
No abstract availableThis publication has 39 references indexed in Scilit:
- Thrombolytic Therapy: Current StatusNew England Journal of Medicine, 1988
- Local intra-arterial fibrinolytic therapy in acute carotid territory stroke. A pilot study.Stroke, 1988
- Activation of the fibrinolytic system during intracoronary streptokinase administrationJournal of the American College of Cardiology, 1987
- Proteolysis of platelet glycoprotein Ib by plasmin is facilitated by plasmin lysine-binding regionsBlood, 1986
- Activation of plasminogen by tissue plasminogen activator on normal and thrombasthenic platelets: effects on surface proteins and platelet aggregationBlood, 1986
- Thrombolytic Therapy for Thromboembolism of Vertebrobasilar ArteryAngiology, 1983
- A comparative randomized trial of heparin versus streptokinase in the treatment of acute proximal venous thrombosis: An interim report of a prospective trialBritish Journal of Surgery, 1979
- A Controlled Clinical Trial of Streptokinase and Heparin in the Treatment of Major Pulmonary EmbolismActa Medica Scandinavica, 1978
- Comparison by Controlled Clinical Trial of Streptokinase and Heparin in Treatment of Life-threatening Pulmonary EmbolismBMJ, 1974
- DEVELOPMENTS IN FIBRINOLYTIC THERAPY FOR THROMBO-EMBOLIC DISEASEAnnals of Internal Medicine, 1959